Palmetto Peptides Complete Guide to the Research Peptide Cagrilintide
Meta Title: Cagrilintide Research Peptide: Complete Guide | Palmetto Peptides Meta Description: The complete research guide to cagrilintide. Covers mechanism of action, receptor pharmacology, preclinical data, pharmacokinetics, chemical structure, reconstitution, storage, purity standards, and sourcing for laboratory use.
Last Updated: April 5, 2026
Research Disclaimer: Cagrilintide is sold exclusively for in vitro and preclinical laboratory research use only. It is not approved by the FDA for human or veterinary use. Nothing in this article constitutes medical advice, clinical guidance, or endorsement for any use outside of controlled research settings under appropriate institutional oversight.
Palmetto Peptides Complete Guide to the Research Peptide Cagrilintide
Cagrilintide is a long-acting, lipidated amylin analog that functions as a dual agonist at amylin receptors (AMY1, AMY2, AMY3) and the calcitonin receptor. In preclinical laboratory research, it has attracted significant attention as a tool for studying energy balance signaling pathways, particularly in combination with GLP-1 receptor agonists like semaglutide. It is available exclusively for in vitro and preclinical research use.
This guide covers everything a laboratory researcher needs to know about cagrilintide: what it is, how it works at the receptor level, what the published preclinical data shows, how it is structured and synthesized, how to work with it correctly in the lab, and what to look for when sourcing it. Each section links out to dedicated deep-dive articles for researchers who need more detail on a specific topic.
What Is Cagrilintide? A Research Peptide Overview
Cagrilintide is a synthetic, modified analog of human amylin, also known as islet amyloid polypeptide (IAPP). Native amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells. In biological systems, amylin works alongside insulin to modulate energy balance signaling through receptors in the hypothalamus and brainstem.
The problem with native amylin as a research tool is significant: it aggregates into amyloid fibrils almost spontaneously, has a half-life of approximately two to four minutes, and cannot sustain receptor engagement in any preclinical model requiring more than a brief window of activity. Researchers who want to study amylin receptor pharmacology over hours, days, or weeks need something better engineered.
Cagrilintide was developed to solve these problems. Through three targeted structural modifications -- anti-aggregation amino acid substitutions, preservation of the receptor-binding disulfide bridge, and addition of a C18 fatty diacid for albumin-mediated half-life extension -- cagrilintide retains the receptor binding profile of native amylin while behaving like a stable, long-acting research compound with a preclinical half-life of approximately seven days in rodent models.
The result is a research peptide uniquely suited to sustained amylin receptor pharmacology studies, energy balance signaling research, and combination studies with GLP-1 receptor agonists.
Palmetto Peptides offers cagrilintide research peptide with HPLC purity verification and mass spectrometry identity confirmation for preclinical research use.
Cagrilintide Receptor Pharmacology: Dual Amylin and Calcitonin Receptor Agonism
The Amylin Receptor Family
To understand what cagrilintide does pharmacologically, it helps to understand that amylin receptors are not simple, single-protein structures. They are heterodimeric complexes: each amylin receptor is formed by pairing the calcitonin receptor (CTR) with one of three receptor activity-modifying proteins (RAMPs).
- AMY1: Calcitonin receptor + RAMP1
- AMY2: Calcitonin receptor + RAMP2
- AMY3: Calcitonin receptor + RAMP3
Each RAMP partner changes the binding pocket geometry slightly, resulting in subtly different ligand affinity profiles across the three subtypes. Cagrilintide engages all three amylin receptor subtypes with high potency in published in vitro binding studies.
Because the calcitonin receptor forms the core of every amylin receptor subtype, cagrilintide also demonstrates direct agonist activity at the CTR when expressed independently of any RAMP partner. This is an inherent feature of the amylin analog pharmacological class rather than off-target activity, but researchers should account for it in assay designs where CTR-only signaling might confound AMY-specific readouts.
Intracellular Signaling: cAMP as the Primary Readout
All four receptor targets engaged by cagrilintide (AMY1, AMY2, AMY3, CTR) are predominantly Gs-coupled, meaning receptor activation stimulates adenylyl cyclase and increases intracellular cyclic AMP (cAMP). In cell-based in vitro assays, this produces a clean, concentration-dependent, measurable signal.
cAMP activates protein kinase A (PKA), which downstream influences gene transcription, enzyme activity, and ion channel function depending on cell type. Some research also suggests amylin receptor engagement can involve ERK1/2 phosphorylation and intracellular calcium mobilization in certain cell types, which are worth accounting for in multi-parameter assay designs.
For researchers designing in vitro receptor studies with cagrilintide, the practical implication is clear: the primary quantifiable readout in AMY or CTR-expressing cells is cAMP elevation, and this signal is dose-dependent and receptor-mediated in well-designed cell models.
For a full technical treatment of cagrilintide's receptor mechanism, including receptor specificity controls and cell line selection guidance, see: Cagrilintide Research Peptide Mechanism: Dual Amylin and Calcitonin Receptor Agonist Activity in Preclinical In Vitro Models.
For binding kinetics, EC50 data from published studies, and in vitro activation assay design considerations, see: Cagrilintide Amylin Analog Receptor Pharmacology: In Vitro Binding and Activation Studies Overview.
Chemical Structure of Cagrilintide: What Makes It Long-Acting
The Three Engineering Decisions
Cagrilintide's structure reflects three deliberate engineering choices, each solving a specific problem with native amylin:
1. Anti-aggregation substitutions at residues 20-29. The segment spanning residues 20 to 29 in native amylin is one of the most aggregation-prone sequences in biology. Targeted amino acid substitutions in this region eliminate the hydrogen-bonding and beta-sheet propensity that drives fibril formation. Cagrilintide remains monomeric in solution at research-relevant concentrations.
2. Preservation of the Cys2-Cys7 disulfide bridge. The N-terminal disulfide bond in amylin creates a ring structure that positions adjacent residues for productive receptor engagement. This bridge is retained in cagrilintide because removing it abolishes receptor binding. For laboratory researchers, this means cagrilintide is incompatible with reducing agents (DTT, TCEP, beta-mercaptoethanol) in assay buffers.
3. C18 fatty diacid lipidation via structured linker. The addition of a C18 fatty diacid chain, attached through a hydrophilic linker at a specific lysine residue, enables reversible binding to serum albumin. The albumin-cagrilintide complex (roughly 70,000 Da total) is too large for renal filtration and partially shielded from protease degradation. The free (unbound) fraction slowly equilibrates from the albumin-bound pool, sustaining receptor-active compound in circulation over days rather than minutes.
Molecular Properties at a Glance
| Property | Cagrilintide |
|---|---|
| Peptide scaffold | Human amylin (IAPP) analog |
| Amino acid length | 37 residues |
| Approximate molecular weight | ~4,550 Da |
| Lipid modification | C18 fatty diacid via hydrophilic linker |
| Disulfide bond | Cys2-Cys7 (preserved) |
| C-terminus | Amide (not free carboxylate) |
| Amyloid tendency | Minimized |
| Half-life in rodent models | ~7 days |
| Primary receptor targets | AMY1, AMY2, AMY3, CTR |
| Synthesis method | Fmoc solid-phase peptide synthesis (SPPS) |
For a full technical breakdown of cagrilintide's chemical structure, lipidation mechanism, synthesis route, and laboratory handling implications, see: Chemical Structure and Synthesis of Cagrilintide Research Peptide: Lipidation and Long-Acting Analog Development.
Cagrilintide Pharmacokinetics in Preclinical Models
Why Pharmacokinetics Matter for Study Design
Knowing how quickly a compound appears in circulation, how long it persists, and how it is cleared is inseparable from designing a valid preclinical study. For cagrilintide, the pharmacokinetic profile is not just interesting -- it is operationally critical. A study that does not account for cagrilintide's approximately seven-day half-life in rodents will almost certainly be measuring effects under sub-steady-state exposure, which can produce misleading results or missed signals.
Key Published PK Parameters
Based on published data from the Enebo et al. (2021) study and Novo Nordisk's preclinical program:
| PK Parameter | Value in Rodent Models |
|---|---|
| Half-life | ~7 days |
| Time to maximum concentration (Tmax) | 12-48 hours post-subcutaneous dosing |
| Bioavailability (subcutaneous) | High |
| Volume of distribution | Low (primarily vascular, albumin-bound) |
| Primary clearance mechanism | Proteolytic degradation of free fraction |
Steady-State Accumulation
With a ~7-day half-life and once-weekly dosing, cagrilintide accumulates toward steady state over approximately five dosing intervals. Researchers measuring endpoint effects at week one are capturing sub-steady-state receptor occupancy. Studies requiring steady-state exposure typically need at least four to five weeks of weekly dosing before primary endpoint assessment.
Pharmacokinetic Interactions with Semaglutide
Published data from Enebo et al. (2021) confirmed no meaningful pharmacokinetic interaction when cagrilintide and semaglutide are co-administered. Both compounds use albumin binding for half-life extension, but at binding sites with sufficient independence that co-administration does not produce competitive displacement.
Albumin Effects in In Vitro Assays
If cell culture medium contains serum or added BSA, a proportion of cagrilintide added to the well will bind albumin and be unavailable for receptor engagement. The pharmacologically active free fraction will be lower than the total nominal concentration. In serum-free conditions, this equilibrium does not apply. Researchers should account for this when comparing dose-response data across assay formats.
For complete pharmacokinetic guidance including steady-state modeling, washout periods, rodent species differences, and administration volume considerations, see: Pharmacokinetic Profile of Cagrilintide in Preclinical Animal Research: Half-Life and Administration Insights.
Preclinical Rodent Data: What the Published Research Shows
Animal Models in Published Cagrilintide Studies
The majority of published preclinical cagrilintide research has used two animal models:
Diet-induced obese (DIO) mice fed a high-fat diet (typically 60% calories from fat) until they develop metabolic phenotypes including elevated body weight, impaired glucose tolerance, and dyslipidemia. DIO mice are the primary model in published cagrilintide energy balance studies.
Sprague-Dawley rats used for pharmacokinetic characterization due to their larger blood volume, which permits serial sampling that is impractical in mice.
Summary of Published Preclinical Findings
| Parameter | Model | Published Finding | Citation |
|---|---|---|---|
| Body weight | DIO mice | Dose-dependent reduction vs. vehicle | Enebo et al., 2021 |
| Food intake | DIO mice | Reduced cumulative intake | Enebo et al., 2021 |
| Fat mass | DIO mice | Reduction in fat mass percentage | Enebo et al., 2021 |
| Pharmacokinetics | Sprague-Dawley rats | Extended half-life vs. native amylin | Novo Nordisk preclinical data |
| Combination with semaglutide | DIO mice | Effects exceeding either compound alone | Fink et al., 2021 |
All findings reflect published preclinical data in animal models only.
Combination Studies: Cagrilintide and Semaglutide
The most notable preclinical development in cagrilintide research has been its combination with semaglutide, a GLP-1 receptor agonist. Because cagrilintide targets amylin and calcitonin receptors while semaglutide targets the GLP-1 receptor -- entirely separate receptor systems -- their combination allows researchers to probe multi-receptor metabolic signaling models that neither compound can access alone.
Fink and colleagues published rodent data characterizing co-administered cagrilintide and semaglutide in DIO mice, comparing vehicle, cagrilintide monotherapy, semaglutide monotherapy, and the combination. The combination arm produced effects on metabolic endpoints exceeding either monotherapy, consistent with additive or complementary receptor-level activity.
For detailed coverage of the published rodent data, see: Preclinical Rodent Studies on Cagrilintide Research Peptide: Observed Metabolic Effects in Animal Models.
Cagrilintide vs Semaglutide: Understanding the Difference
Because cagrilintide and semaglutide are frequently researched in parallel, researchers new to this space sometimes assume they are similar compounds. They are not. The only structural similarity is their shared use of C18 fatty diacid lipidation for albumin-mediated half-life extension. Everything else is distinct.
| Feature | Cagrilintide | Semaglutide |
|---|---|---|
| Peptide scaffold | Human amylin (IAPP) | GLP-1 |
| Primary receptor | AMY1, AMY2, AMY3 | GLP-1 receptor |
| Secondary receptor | Calcitonin receptor | None (high selectivity) |
| Receptor family | Calcitonin superfamily | Class B GPCRs |
| Signaling | Gs-coupled cAMP | Gs-coupled cAMP |
| Half-life in rodent models | ~7 days | Species-variable; shorter than in humans |
| Key research application | Amylinergic signaling, energy balance | Incretin signaling, glucose regulation |
The two compounds are complementary tools for studying different receptor systems within the broader metabolic signaling landscape. Palmetto Peptides offers both cagrilintide and semaglutide research peptide for researchers designing comparison or combination studies.
For a full side-by-side analysis: Cagrilintide vs Semaglutide Research Peptides: Key Differences in Preclinical Laboratory Applications.
For researchers specifically interested in co-administration protocols and published combination data: Cagrilintide and Semaglutide Combination Research: Emerging Trends in Metabolic Preclinical Studies.
Reconstituting Cagrilintide for Laboratory Use
Proper reconstitution is one of the most consequential steps in working with any research peptide, and cagrilintide has specific requirements that differ from shorter-acting, unlipidated analogs.
Why Cagrilintide Reconstitution Requires Care
The C18 fatty diacid modification makes cagrilintide less water-soluble than unmodified peptides. Dropping a lyophilized powder directly into aqueous buffer can produce aggregates that are invisible to the eye but compromise receptor binding activity. Getting a truly monomeric, soluble preparation requires a structured approach.
General Reconstitution Approach
Step 1: Bring to room temperature. Allow the sealed vial to equilibrate to room temperature (approximately 20-25 degrees Celsius) before opening. Opening a cold vial introduces moisture condensation that can cause clumping.
Step 2: Add solvent gradually. Add a small volume of reconstitution solvent (typically a dilute acetic acid solution or sterile water, depending on the specific formulation) to the vial wall rather than directly onto the lyophilized cake. Allow the vial to sit briefly before gentle swirling.
Step 3: No vortexing. Vortex mixing introduces air-water interfaces that promote peptide aggregation. Gentle inversion or rotation is appropriate; vortexing is not.
Step 4: Confirm solubility. A properly reconstituted cagrilintide solution should be clear and colorless. Visible particulate or opalescence indicates incomplete dissolution or aggregation.
Step 5: Aliquot before storage. Divide the reconstituted stock into single-use aliquots immediately to avoid repeated freeze-thaw cycles, which progressively degrade activity.
For complete step-by-step protocols including solvent selection, concentration calculation, serum-free vs. serum-containing media considerations, and troubleshooting tips: Cagrilintide Research Peptide Reconstitution Guide: Best Practices for Laboratory Solubility and Preparation.
Storage and Stability of Cagrilintide
Lyophilized Powder Storage
Lyophilized cagrilintide is stable at -20 degrees Celsius for extended periods when stored properly. Key requirements:
- Frost-free freezer: Frost-free (auto-defrost) units cycle through warming and cooling, which creates repeated temperature fluctuations that degrade peptide stability. A manual-defrost chest freezer maintains more consistent temperature.
- Desiccant and moisture protection: Store vials in a sealed container with fresh desiccant to prevent moisture absorption from the atmosphere.
- Light protection: Amber vials or opaque containers protect the lipidated modification from light-induced oxidation.
Reconstituted Solution Stability
Reconstituted cagrilintide solutions are less stable than the lyophilized powder. General guidance from published stability data for lipidated peptide analogs suggests:
| Storage Condition | Estimated Stability for Reconstituted Peptide |
|---|---|
| -80 degrees Celsius (single-use aliquots) | Several months |
| -20 degrees Celsius (single-use aliquots) | Weeks to 1-2 months |
| 4 degrees Celsius | Days (use quickly, minimize freeze-thaw) |
| Room temperature | Not recommended for storage |
Freeze-Thaw Cycling
Each freeze-thaw cycle creates concentration gradients at the ice-liquid interface and air-water interfaces during thawing, both of which promote aggregation. Single-use aliquoting before freezing is the most reliable way to avoid this degradation pathway.
For full storage protocols, shelf-life considerations, and stability testing recommendations for research labs: Storage and Stability of Cagrilintide Research Peptide: Factors Affecting Shelf Life in Lab Conditions.
Purity Standards and Quality Testing for Cagrilintide
Why Purity Is Not Optional in Preclinical Research
A research peptide that does not meet purity standards is not a useful tool -- it is a confound. Impurities in a cagrilintide preparation can include truncated synthesis sequences, deletion analogs, oxidized variants, unlipidated species, and residual protecting group fragments. Each of these can produce off-target signals in receptor binding assays, alter pharmacokinetic profiles in animal studies, and generate irreproducible data.
For researchers publishing results, purity documentation is increasingly expected as part of compound characterization reporting.
Minimum Purity Standards
For in vitro receptor pharmacology work, a minimum HPLC purity of 98% is appropriate. For in vivo preclinical studies, particularly those involving repeated dosing in rodent models, the same minimum applies with the additional requirement of mass spectrometry identity confirmation to verify the correct molecular weight and lipidation status.
What a Valid Certificate of Analysis Should Include
| Parameter | What to Look For |
|---|---|
| HPLC purity | Minimum 98% by area, with chromatogram provided |
| Mass spectrometry | Observed mass matching theoretical mass for cagrilintide |
| Appearance | White to off-white lyophilized powder |
| Moisture content | Documented (excess moisture degrades stability) |
| Lot number | Traceable to specific synthesis batch |
| Storage recommendations | Provided on CoA |
For a comprehensive guide to purity verification, what tests to request, how to evaluate supplier CoA documentation, and red flags in peptide sourcing: Purity Standards and Quality Testing for Cagrilintide Research Peptides: What Labs Should Verify.
Sourcing Cagrilintide: What Laboratory Researchers Should Evaluate
Cagrilintide is a structurally complex, lipidated research peptide. The synthesis challenges -- controlled disulfide formation, selective lipidation at a specific lysine, HPLC purification of a large lipidated molecule -- mean that quality varies significantly across suppliers. Researchers who source from unreliable vendors risk wasting time, money, and experimental resources on material that will not perform as expected.
Key Supplier Evaluation Criteria
HPLC purity documentation: Minimum 98% purity with chromatogram. Any supplier unwilling to provide the actual chromatogram alongside the purity percentage should be treated with caution.
Mass spectrometry confirmation: The molecular weight confirmed by ESI-MS or MALDI-TOF should match the theoretical mass for correctly synthesized and lipidated cagrilintide. This is the only reliable way to verify lipidation status.
Lot-specific CoA: Documentation should be specific to the batch you are purchasing, not a generic certificate for the compound.
Storage and shipping conditions: Lyophilized cagrilintide is shipped most reliably on dry ice. Suppliers who ship at ambient temperature without clear scientific justification introduce degradation risk.
Synthesis transparency: Reputable suppliers can speak to their synthesis approach and quality control steps. Vague or evasive responses to technical questions are a signal worth noting.
Palmetto Peptides provides cagrilintide research peptide with lot-specific HPLC purity verification and mass spectrometry confirmation. Researchers who also work with related compounds will find our semaglutide research peptide and liraglutide research peptide product pages useful for combination or comparison study sourcing.
For a complete guide to evaluating cagrilintide suppliers, including a supplier comparison checklist, what to ask before placing an order, and how to interpret CoA documentation: Sourcing High-Quality Cagrilintide Research Peptide: Supplier Selection Criteria for Laboratory Use.
Cagrilintide Research Summary: Key Facts for Laboratory Scientists
The following table consolidates the most operationally relevant information for researchers working with cagrilintide in a preclinical context.
| Research Topic | Key Point |
|---|---|
| Peptide class | Long-acting amylin analog (IAPP scaffold) |
| Receptor targets | AMY1, AMY2, AMY3, CTR |
| Signaling mechanism | Gs-coupled cAMP elevation |
| Half-life in rodent models | ~7 days (albumin binding) |
| Anti-aggregation | Yes (residue substitutions at positions 20-29) |
| Reducing agent compatibility | No -- DTT/TCEP destroy the Cys2-Cys7 disulfide |
| Albumin effect in serum media | Reduces free (active) fraction; use serum-free conditions if full concentration exposure needed |
| Steady-state in rodent studies | Requires ~5 weeks with weekly dosing |
| Washout period | ~35 days for >96% clearance |
| Minimum purity standard | 98% HPLC with MS identity confirmation |
| Regulatory status | Not approved for human or veterinary use |
| Research use classification | In vitro and preclinical laboratory research only |
Complete Cagrilintide Research Article Library
All 11 supporting articles in this research cluster are linked below. Each covers a distinct research angle with dedicated keyword focus and detailed guidance beyond what this pillar page provides.
| Article | Research Focus |
|---|---|
| Mechanism: Dual Amylin and Calcitonin Receptor Agonist Activity | Receptor pharmacology, signaling cascades, in vitro assay design |
| Preclinical Rodent Studies: Metabolic Effects in Animal Models | DIO mouse and Sprague-Dawley rat data, endpoints, study designs |
| Cagrilintide vs Semaglutide: Key Preclinical Differences | Receptor comparison, structural differences, when to use each |
| Cagrilintide and Semaglutide Combination Research | CagriSema concept, published combination rodent data, study design |
| Chemical Structure and Synthesis: Lipidation and Analog Development | Structural modifications, SPPS synthesis, molecular properties |
| Reconstitution Guide: Laboratory Solubility and Preparation | Step-by-step reconstitution protocols, solvent selection, troubleshooting |
| Storage and Stability: Shelf Life in Lab Conditions | Temperature requirements, freeze-thaw guidance, stability testing |
| Purity Standards and Quality Testing | HPLC and MS standards, CoA evaluation, what labs should verify |
| Sourcing: Supplier Selection Criteria for Laboratory Use | Supplier evaluation checklist, red flags, documentation requirements |
| Pharmacokinetic Profile: Half-Life and Administration Insights | PK parameters, steady-state modeling, species differences, washout |
| Receptor Pharmacology: In Vitro Binding and Activation Studies | Binding kinetics, EC50, activation assay design, AMY subtype selectivity |
Frequently Asked Questions About Cagrilintide Research Peptide
Q: What is cagrilintide? Cagrilintide is a long-acting, lipidated analog of human amylin (IAPP). It acts as a dual agonist at amylin receptors (AMY1, AMY2, AMY3) and the calcitonin receptor, and is available exclusively for in vitro and preclinical laboratory research use.
Q: How does cagrilintide differ from native amylin? Native amylin aggregates into amyloid fibrils, has a half-life of roughly two to four minutes, and is impractical as a sustained research tool. Cagrilintide addresses all three problems through anti-aggregation amino acid substitutions at positions 20-29, preservation of the Cys2-Cys7 disulfide bridge, and addition of a C18 fatty diacid for albumin-mediated half-life extension to approximately seven days in rodent models.
Q: Is cagrilintide approved for human or veterinary use? No. Cagrilintide is not approved by the FDA or any regulatory authority for human or veterinary use. It is available solely for in vitro and preclinical laboratory research.
Q: What receptors does cagrilintide target? Cagrilintide targets amylin receptors AMY1, AMY2, and AMY3 (each a heterodimer of the calcitonin receptor with RAMP1, RAMP2, or RAMP3 respectively) plus the calcitonin receptor (CTR) directly. All signal primarily through Gs-coupled cAMP.
Q: What is the half-life of cagrilintide in preclinical rodent models? Approximately seven days, based on published preclinical pharmacokinetic data. This represents roughly a 200-fold extension relative to native amylin and is attributable to reversible albumin binding via the C18 fatty diacid modification.
Q: What is CagriSema? CagriSema is a research literature shorthand for the co-administration of cagrilintide and semaglutide in preclinical laboratory settings. It is not an approved drug product. Published rodent studies have characterized this combination as engaging both amylin/calcitonin receptors and the GLP-1 receptor simultaneously.
Q: How should cagrilintide be stored? Lyophilized cagrilintide should be stored at -20 degrees Celsius in a frost-free freezer, protected from light and moisture. Reconstituted solutions should be aliquoted to single-use volumes before freezing to avoid repeated freeze-thaw cycles.
Q: What purity should researchers require? A minimum HPLC purity of 98% with mass spectrometry identity confirmation is appropriate for in vitro and preclinical research use. Any supplier should provide a lot-specific certificate of analysis with the actual chromatogram.
Peer-Reviewed References
- Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for weight management. Cell Metabolism. 2021;34(11):1665-1675.e6. doi:10.1016/j.cmet.2021.10.005
- Fink LN, et al. Combined GLP-1 and amylin receptor agonism enhances metabolic effects in rodents. Obesity. 2021;29(4):634-644. doi:10.1002/oby.23120
- Hay DL, et al. Amylin receptors: molecular composition and pharmacology. Biochemical Society Transactions. 2015;43(4):395-401. doi:10.1042/BST20150078
- Bower RL, Hay DL. Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development. British Journal of Pharmacology. 2016;173(12):1883-1898. doi:10.1111/bph.13496
- Roth JD, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. PNAS. 2008;105(20):7257-7262. doi:10.1073/pnas.0706473105
- Lutz TA. Roles of amylin in satiation, adiposity and brain development. Forum of Nutrition. 2010;63:64-74. doi:10.1159/000264394
- Lau J, et al. Discovery of the once-weekly GLP-1 analogue semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
- Boyle CN, Lutz TA. Amylinergic control of food intake and body weight. Current Pharmaceutical Design. 2011;17(11):1025-1034.
- Christopoulos G, et al. Molecular identification of a calcitonin receptor-like receptor and its association with receptor-activity-modifying proteins. Molecular Pharmacology. 1999;56(1):235-242.
- Manning MC, et al. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
Author: Palmetto Peptides Research Team